Vancouver, British Columbia--(Newsfile Corp. - March 30, 2022) - SURENANO SCIENCE LTD. (CSE: SURE) (the "Company" or "SureNano") is pleased to announce that it will be speaking at the Delta 8 Expo and Delta 9 Expo in partnership with the CBD Expo TOUR on March 30 to April 1, 2022, in Dallas, Texas at the Hyatt Regency in Downtown Dallas. The Company will be exhibiting at booth #145 by the Extraction Stage.

The event will bring together 80+ exhibitors presenting and sampling some of the latest Delta 8, Hemp-Derived Delta 9, and CBD products out in the market. Expected attendance at the B2B-focused show is expected to be over 3,000. Panel discussions will be held hourly on two days of the event discussing cannabinoid science, entrepreneurship, marketing, lifestyle medicine, neuroscience, and extraction equipment innovations.

Mark Scott, director of SureNano, will be speaking at the CBD Expo to a crowd of industry leaders in the extraction and purification of the federally legalized hemp industry. He will be presenting on the Extraction Stage at 12:30 PM on Thursday, March 31. He will be outlining the strategic value of nano emulsions, such as those that are made with our exceptional SureNanoTM emulsifier, in creating sustainable margins and revenues in a time of widespread commoditization and price erosion for extractors.

Mr. Scott will be highlighting the surging consumer demand for products which feature attributes that can only be powered by nano emulsions. Attributes like being reliably fast-acting or having consistently predictable dosing. He will introduce the abundant opportunities for brand differentiation that can result from leveraging the commercial power of nano emulsions, and the importance to be first-to-market leaders in segments with excellent long-term potential that currently contain no competition at all.

The business of SureNano Science Ltd. is the sale and distribution of the SureNano™ surfactant, which is a ready-to-mix food grade compound that provides the base for high performance nano-emulsions to create incredibly homogeneous and stable products while maximizing bioavailability, clarity, and taste. The Company has an exclusive license to distribute the SureNanoTM surfactant within Canada and Colorado, USA.

ON BEHALF OF SURENANO SCIENCE LTD.

"Charles MaLette" CEO, President, Director & Secretary T: 604-428-5171 E: info@surenano.com

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of SureNano. Forward-looking information is based on certain key expectations and assumptions made by the management of SureNano. In some cases, you can identify forward-looking statements by the use of words such as "will," "may," "would," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "could" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements in this press release include that (a) The event will bring together 80+ exhibitors, (b) Expected attendance at the B2B-focused show is expected to be over 3,000, (c) Panel discussions will be held hourly on both days of the event, (d) Mark Scott, director of SureNano, will be speaking at the CBD Expo, (e) Mr. Scott will be presenting on the Extraction Stage at 12:30 PM on Thursday, March 31, (f) Mr. Scott will be outlining the strategic value of nano emulsions, and (g) Mr. Scott will be highlighting the surging consumer demand for products which feature attributes that can only be powered by nano emulsions. Although SureNano believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because SureNano can give no assurance that they will prove to be correct.

The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/118589

Cassava Sciences, Inc.'s (NASDAQ:SAVA) a clinical stage biotechnology company, is developing a drug for Alzheimer - a neurodegenerative disease, affecting more than 35.7 million people worldwide (6 million in the US). In this article, we will review Cassava's product line and cash capacity to fund further research until FDA approval.

Biotech stocks are down big since last summer. The media's focus on gene editing, messenger RNA (mRNA), and monoclonal antibodies may have waned, but some patients are already benefiting. Admittedly, shares of Regeneron are doing just fine.

Much as Intuitive Surgical redefined the surgical field, this company is updating how abnormal heart rhythms are diagnosed.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has granted Marketing Authorization for the expanded use of PrTRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include children with cystic fibrosis (CF) ages 6 through 11 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. With this announcement, approximately 500 Canadians with CF ages 6-11 are now eligible for TRIKAFTA®. As a resul

Sunshine Biopharma Inc. (NASDAQ: SBFM) might be living the concept of being in the right place at the right time. This Canadian company is currently focusing on three product lines - the SBFM-PL4 COVID-19 treatment, the Adva-27a anticancer compound, and the Essential 9 nutritional supplements — and each is moving forward with positive results. In February, the company successfully closed an $8 million public offering and was uplisted to the Nasdaq Capital Market. Also, in February, the company e

Photo Illustration by The Daily Beast/GettyThanks to the success of an initial safety trial for an implantable device that can translate the brain’s electrical impulses into readable signals, we’re a step closer to being able to text—or otherwise interface with our devices—using just our thoughts.Best of all, this new brain-computer interface (BCI)—“brain modem,” if you will—doesn’t require a hole in your head. It does, however, require a hole in your chest. And that’s just one factor that could

The Omicron variant was predominant during Moderna's pediatric trial, and the drugmaker said two doses were around 38% effective in preventing infections in 2 to 5-year-olds and 44% effective for children aged 6 months to under 2 years. Last week, Pfizer Inc and BioNTech said a third dose of the COVID-19 vaccine produced significant protection against the Omicron variant in healthy children from ages 5 to 11. Earlier this year, the U.S. Food & Drug Administration authorized a third dose of the Pfizer/BioNTech vaccine for children ages 12 to 15 and those aged 5 through 11 who are immunocompromised.

The company's immunology drug Rinvoq was given the go-ahead to treat adult patients with moderate-to-severe ulcerative colitis.

Former surgeon general Jerome Adams is dubbing this month’s Gridiron Club dinner in Washington a “public health disaster” that should serve as a teachable moment. “A mass gathering occurring during a global pandemic — attended by government leaders, members of the media who’ve regularly reported on the pandemic, and even the Centers of Disease Control Prevention director and…

As mandates end, people are relying on one-way masking

Novavax, which is still awaiting a federal decision for its stand-alone Covid vaccine, received early results that suggest it can move forward with its testing for the single shot for both viruses.

The new BA.2.12.1 variant accounted for 19% of COVID cases in the U.S. last week, sharply increasing its spread from the week before.

COVID-19 cases are up more than 50% from three weeks ago in Ohio. Here's what Ohioans need to know for the next wave of the virus.

Is Merck stock a buy after the company guided to $10 billion in sales from its heart drugs? Is MRK stock a buy right now?

NHS transgender treatment for children is "bordering on ideological", Sajid Javid has warned.

State health officials say they are more concerned with hospitalizations, which are projected to be well below previous peaks.

We talked to two gut-health experts to find out what prebiotics are, how they can help with your riding performance, and what the best sources are.

Fauci, who has consulted multiple presidents about pandemics, weighs in on the end of mask mandates and the future of the pandemic.

The support from Weibo users towards Wang Sicong, meanwhile, are indications of some citizens' boiling discontent about Beijing's zero-covid policy.

Shares of the clinical-stage cancer specialist Checkpoint Pharmaceuticals (NASDAQ: CMPI) are up by a handsome 328% as of 1:41 p.m. ET Tuesday afternoon. The drugmaker's shares are racing higher today in response to a $250 million all-cash buyout offer from Regeneron Pharmaceuticals (NASDAQ: REGN). Regeneron's tender offer of $10.50 per share represents a whopping 332% premium relative to Checkpoint Pharmaceuticals' closing price Monday afternoon.